You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

284 Results
Document
Sep 2019
Document
Sep 2019
Document
Sep 2019
Document
Sep 2019
Document
Sep 2019
Document
Sep 2019
Document
Oct 2019
Blog post
Dr. Edward Kucharski Among the many healthcare challenges facing trans and non-binary people, cancer poses a multi-edge threat. Not only are trans...
Nov 2019
Guidelines and Advice
Status: Current
ID: N/A
Version: 2
Jan 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - in Combination with Venetoclax for Previously Untreated Chronic Lymphocytic Leukemia
Exceptional Access Program
    venetoclax - in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
oBINutuzumab,
venetoclax
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2023

Pages